PSMA-Targeted Cancer Immunotherapy Patent Granted to Methodist Hospital
Summary
The USPTO granted patent US12605446B2 to The Methodist Hospital covering engineered cells with chimeric antigen receptors (CARs) targeting PSMA for prostate cancer treatment. The patent, filed August 20, 2021, contains 15 claims and names Bin He as inventor. This grant confers exclusive IP rights for PSMA-targeted CAR-T immunotherapies in the United States.
“Disclosed are engineered cells comprising chimeric antigen receptors and uses thereof for treating prostate cancer.”
What changed
The USPTO issued patent US12605446B2 to The Methodist Hospital, granting exclusive intellectual property rights for PSMA (prostate-specific membrane antigen)-targeted chimeric antigen receptor (CAR) immunotherapies for prostate cancer. The patent covers engineered cells expressing these CARs and their therapeutic uses.
Companies developing PSMA-targeted cellular immunotherapies or prostate cancer treatments should conduct freedom-to-operate analyses before advancing programs, as this granted patent may encumber similar approaches. The Methodist Hospital holds enforceable exclusion rights in the US market for the claimed scope, which includes engineered cell compositions targeting PSMA for cancer treatment.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PSMA-targeted immunotherapies for cancers
Grant US12605446B2 Kind: B2 Apr 21, 2026
Assignee
The Methodist Hospital
Inventors
Bin He
Abstract
Disclosed are engineered cells comprising chimeric antigen receptors and uses thereof for treating prostate cancer.
CPC Classifications
A61K 40/15 A61K 40/11 A61K 40/31 A61K 40/4211 A61K 40/4273 A61K 40/4276 A61K 2239/31 A61K 2239/38 A61K 2239/57 A61K 2239/58 A61P 35/00 C07K 16/3069 C07K 2317/622 C07K 2319/03 C07K 14/7051 C12N 5/0636 C12N 2501/15 C12N 2501/515 C12N 2510/00
Filing Date
2021-08-20
Application No.
18032485
Claims
15
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.